Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results

<p>Patient demographics and tumor characteristics at baseline and at surgery, by randomized treatment group.</p>

保存先:

書誌詳細
第一著者:	Nigel Bundred (15046233) (author)
その他の著者:	Nuria Porta (15029895) (author), Adrian Murray Brunt (15046236) (author), Angela Cramer (5870894) (author), Andrew Hanby (25460) (author), Abeer M. Shaaban (15046239) (author), Emad A. Rakha (7957955) (author), Anne Armstrong (15045410) (author), Ramsey I. Cutress (15046242) (author), David Dodwell (15046245) (author), Marie A. Emson (15046248) (author), Abigail Evans (7421527) (author), Sue M. Hartup (15046251) (author), Kieran Horgan (15030513) (author), Sarah E. Miller (15046254) (author), Stuart A. McIntosh (11368948) (author), James P. Morden (7594370) (author), Jay Naik (15046257) (author), Sankaran Narayanan (15046260) (author), Jane Ooi (15046263) (author), Anthony I. Skene (15046266) (author), David A. Cameron (6277425) (author), Judith M. Bliss (8827107) (author)
出版事項:	2025
主題:	Cancer Cancer Detection and Diagnosis Clinical Research and Trials Biomarkers Prognostic biomarkers Breast Cancer Clinical Trial Results Phase II clinical trials Precision Medicine
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
著者:: Nigel Bundred (15046233)
出版事項: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
著者:: Nigel Bundred (15046233)
出版事項: (2025)

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
著者:: Nigel Bundred (15046233)
出版事項: (2025)

Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
著者:: Nigel Bundred (15046233)
出版事項: (2025)

Table S1-S8 from Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer
著者:: Ruiyun Zhang (17142498)
出版事項: (2025)

Supplementary Figure S1 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
著者:: Rohit Thummalapalli (17314483)
出版事項: (2025)

Supplementary Figure S10 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
著者:: Rohit Thummalapalli (17314483)
出版事項: (2025)

Supplementary Figure S11 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
著者:: Rohit Thummalapalli (17314483)
出版事項: (2025)

Supplementary Figure S12 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
著者:: Rohit Thummalapalli (17314483)
出版事項: (2025)

Supplementary Figure S13 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
著者:: Rohit Thummalapalli (17314483)
出版事項: (2025)

Supplementary Figure S14 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
著者:: Rohit Thummalapalli (17314483)
出版事項: (2025)

Supplementary Figure S15 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
著者:: Rohit Thummalapalli (17314483)
出版事項: (2025)

Supplementary Figure S2 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
著者:: Rohit Thummalapalli (17314483)
出版事項: (2025)

Supplementary Figure S3 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
著者:: Rohit Thummalapalli (17314483)
出版事項: (2025)

Supplementary Figure S4 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
著者:: Rohit Thummalapalli (17314483)
出版事項: (2025)

Supplementary Figure S5 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
著者:: Rohit Thummalapalli (17314483)
出版事項: (2025)

Supplementary Figure S6 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
著者:: Rohit Thummalapalli (17314483)
出版事項: (2025)

Supplementary Figure S7 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
著者:: Rohit Thummalapalli (17314483)
出版事項: (2025)

Supplementary Figure S8 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
著者:: Rohit Thummalapalli (17314483)
出版事項: (2025)

Supplementary Figure S9 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
著者:: Rohit Thummalapalli (17314483)
出版事項: (2025)

Supplementary Table S3 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
著者:: Rohit Thummalapalli (17314483)
出版事項: (2025)

Supplementary Table S4 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
著者:: Rohit Thummalapalli (17314483)
出版事項: (2025)

Supplementary Figure S1 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
著者:: Kala Visvanathan (14952973)
出版事項: (2025)

Supplementary Figure S2 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
著者:: Kala Visvanathan (14952973)
出版事項: (2025)

Supplementary Figure S3 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
著者:: Kala Visvanathan (14952973)
出版事項: (2025)

Supplementary Figure S4 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
著者:: Kala Visvanathan (14952973)
出版事項: (2025)

Supplementary Figure S5 from Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
著者:: Kala Visvanathan (14952973)
出版事項: (2025)

Supplementary Data 1 from Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis
著者:: Nam Q. Bui (14958210)
出版事項: (2025)

Figure S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
著者:: Laura Boucai (15054310)
出版事項: (2025)

Figure S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
著者:: Laura Boucai (15054310)
出版事項: (2025)

Figure S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
著者:: Laura Boucai (15054310)
出版事項: (2025)

Figure S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
著者:: Laura Boucai (15054310)
出版事項: (2025)

Table S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
著者:: Laura Boucai (15054310)
出版事項: (2025)

Table S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
著者:: Laura Boucai (15054310)
出版事項: (2025)

Table S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
著者:: Laura Boucai (15054310)
出版事項: (2025)

Table S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
著者:: Laura Boucai (15054310)
出版事項: (2025)

Table S5 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
著者:: Laura Boucai (15054310)
出版事項: (2025)

Table S6 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
著者:: Laura Boucai (15054310)
出版事項: (2025)

Supplementary Figure S1 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
著者:: Ulka N. Vaishampayan (15051039)
出版事項: (2025)

Supplementary Figure S2 from Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer
著者:: Ulka N. Vaishampayan (15051039)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_60imgpih5ufgfgtdt1ihb9jaif